Literature DB >> 18588935

Parenteral administration of RF 8-2/6/7 rotavirus-like particles in a one-dose regimen induce protective immunity in mice.

Claudia Istrate1, Jorma Hinkula, Annie Charpilienne, Didier Poncet, Jean Cohen, Lennart Svensson, Kari Johansen.   

Abstract

Rotavirus virus-like particles (RV-VLPs) represent a novel strategy for development of a rotavirus subunit vaccine. In this study, RF 8-2/6/7-VLPs with rotavirus VP8 protein (amino acid 1-241 of VP4) fused to the amino terminal end of a truncated VP2, were evaluated for their immunogenic and protective properties. A single intramuscular dose of, either 2 or 20 microg, RF 8-2/6/7-VLPs alone or combined with a potent adjuvant poly[di(carboxylatophenoxy)]phosphazene] (PCPP) induced rotavirus-specific serum IgG and IgA, fecal IgG titers that were enhanced 5-90-fold by adjuvant. Passive protective immunity was achieved in offspring to dams vaccinated with 2 and 20 microg RV-VLPs in presence of adjuvant and 20 microg RV-VLP without adjuvant.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18588935     DOI： 10.1016/j.vaccine.2008.05.089

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  14 in total

1.  Production of human rotavirus and Salmonella antigens in plants and elicitation of fljB-specific humoral responses in mice.

Authors:  Louis-Philippe Bergeron-Sandoval; Aurélie Girard; François Ouellet; Denis Archambault; Fathey Sarhan
Journal:  Mol Biotechnol       Date:  2011-02       Impact factor: 2.695

2.  Immunogenicity and protective efficacy of rotavirus VP8* fused to cholera toxin B subunit in a mouse model.

Authors:  Miaoge Xue; Linqi Yu; Lianzhi Jia; Yijian Li; Yuanjun Zeng; Tingdong Li; Shengxiang Ge; Ningshao Xia
Journal:  Hum Vaccin Immunother       Date:  2016-07-19       Impact factor: 3.452

3.  Expression of human rotavirus chimeric fusion proteins from replicating but non disseminating adenovectors and elicitation of rotavirus-specific immune responses in mice.

Authors:  Aurélie Girard; Elodie Roques; Marie-Claude St-Louis; Bernard Massie; Denis Archambault
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

4.  The performance of licensed rotavirus vaccines and the development of a new generation of rotavirus vaccines: a review.

Authors:  Yuxiao Wang; Jingxin Li; Pei Liu; Fengcai Zhu
Journal:  Hum Vaccin Immunother       Date:  2020-09-23       Impact factor: 3.452

5.  Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP.

Authors:  Sarah M Valencia; Athina Zacharia; Alexander Marin; Rebecca L Matthews; Chia-Kuei Wu; Breana Myers; Chelsea Sanders; Simone Difilippantonio; Reinhard Kirnbauer; Richard B Roden; Ligia A Pinto; Robert H Shoemaker; Alexander K Andrianov; Jason D Marshall
Journal:  Hum Vaccin Immunother       Date:  2021-02-11       Impact factor: 3.452

Review 6.  Polyphosphazene immunoadjuvants: Historical perspective and recent advances.

Authors:  Alexander K Andrianov; Robert Langer
Journal:  J Control Release       Date:  2020-12-05       Impact factor: 9.776

Review 7.  Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes.

Authors:  Bradford S Powell; Alexander K Andrianov; Peter C Fusco
Journal:  Clin Exp Vaccine Res       Date:  2015-01-30

8.  Chimaeric virus-like particles derived from consensus genome sequences of human rotavirus strains co-circulating in Africa.

Authors:  Khuzwayo C Jere; Hester G O'Neill; A Christiaan Potgieter; Alberdina A van Dijk
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

9.  Engineering and expression of a human rotavirus candidate vaccine in Nicotiana benthamiana.

Authors:  Francisco F P G Pêra; David L R Mutepfa; Ayesha M Khan; Johann H Els; Sandiswa Mbewana; Alberdina A A van Dijk; Edward P Rybicki; Inga I Hitzeroth
Journal:  Virol J       Date:  2015-12-02       Impact factor: 4.099

Review 10.  Engineered biological entities for drug delivery and gene therapy protein nanoparticles.

Authors:  Joan Domingo-Espín; Ugutz Unzueta; Paolo Saccardo; Escarlata Rodríguez-Carmona; José Luís Corchero; Esther Vázquez; Neus Ferrer-Miralles
Journal:  Prog Mol Biol Transl Sci       Date:  2011       Impact factor: 3.622
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.